Professional Article
previous document  unige:78439  next document
add to browser collection
Title

Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)

Authors
Costedoat-Chalumeau, Nathalie
Galicier, Lionel
Aumaître, Olivier
Francès, Camille
Le Guern, Véronique
Lioté, Frédéric
Smail, Amar
Limal, Nicolas
show hidden authors show all authors [1 - 30]
Published in Annals of the Rheumatic Diseases. 2013, vol. 72, no. 11, p. 1786-92
Abstract Hydroxychloroquine (HCQ) is an important medication for treating systemic lupus erythematosus (SLE). Its blood concentration ([HCQ]) varies widely between patients and is a marker and predictor of SLE flares. This prospective randomised, double-blind, placebo-controlled, multicentre study sought to compare standard and adjusted HCQ dosing schedules that target [HCQ] ≥1000 ng/ml to reduce SLE flares.
Keywords AdultAntirheumatic Agents/administration & dosage/bloodDose-Response Relationship, DrugDouble-Blind MethodDrug Monitoring/methodsFemaleFranceHumansHydroxychloroquine/administration & dosage/bloodLupus Erythematosus, Systemic/drug therapyMaleMiddle AgedProspective StudiesTreatment Outcome
Identifiers
PMID: 23144449
Full text
Article (Published version) (367 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research group Groupe Perrier Arnaud (Médecine interne générale, de réhabilitation et de gériatrie) (585)
Citation
(ISO format)
COSTEDOAT-CHALUMEAU, Nathalie et al. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). In: Annals of the Rheumatic Diseases, 2013, vol. 72, n° 11, p. 1786-92. https://archive-ouverte.unige.ch/unige:78439

161 hits

0 download

Update

Deposited on : 2015-12-09

Export document
Format :
Citation style :